Impact of endocrine therapy on lipid metabolism and bone metabolism of prostate cancer patients -Comparison with chlormadinone acetate and bicalutamide- - Impact of endocrine therapy on lipid metabolism and bone metabolism of prostate cancer patients

agasaki University Hospital0 个研究点目标入组 100 人开始时间: 2015年8月10日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1. Those who have received those who had received endocrine therapy current or against prostate cancer in the past. 2. A person who has received chemotherapy in the past. 3. A person who has been treated with estrogen agent in the past. 4. Those who received radiation therapy to the primary tumor or metastases within the past 3 months. 5. Of a person merger or suspicion of clinically important liver disease or symptomatic of hepatobiliary disease. 6. Those who have developed ischemic heart disease within 6 months 7. A person having control difficult complications (heart disease, severe diabetes, bleeding, etc.). 8. Administration contraindication: CMA, Bicalutamide, goserelin acetate, acetic acid leuprorelin 9. Those of active double cancer. 10. There is a thrombotic predisposition, or person who has a thrombosis. 11. Registration within 28 days prior person who has used other investigational drugs and clinical trials for medical equipment and post-marketing clinical study drug. 12. Person who is pregnant or lactating Person judged as unsuitable for the study by the investigator

发起方

agasaki University Hospital